IsoPlexis Adds Infectious Disease Pioneer Dr. David Ho to its Scientific Advisory Board

BRANFORD, Conn., March 14, 2017 /PRNewswire-USNewswire/ -- IsoPlexis Corporation (IsoPlexis), a venture capital-funded life sciences company dedicated to accelerating the fight against cancer, autoimmune disease, infectious disease and more through a precision single-cell detection platform, today announced the appointment of Dr. David Ho to its Scientific Advisory Board. Dr. Ho is a recognized pioneer in the infectious disease area. He has authored more than 400 publications, was named Time magazine's 1996 Man of the Year for his pioneering work in AIDS research and is the recipient of 12 honorary doctorates for his scientific contributions.

IsoPlexis Chief Executive Officer Sean Mackay said, "Dr. David Ho is a critical addition to our Scientific Advisory Board. As we venture into broader applications in infectious disease and beyond, his position as a thought leading scientist will help us to accelerate efforts to combat these diseases."

IsoPlexis Scientific Advisory Board Chair Dr. Rong Fan, an associate professor of Biomedical Engineering at Yale, added, "With Dr. Ho, our scientific board has added a truly eminent scientist with proven success in harnessing the power of immunology to address life-threatening diseases and ailments."

Dr. David Ho is the founding Scientific Director and Chief Executive Officer of the Aaron Diamond AIDS Research Center. His lab helped pioneer the field of quantitation of HIV among infected individuals. In the last decade, his research team extended this work and revolutionized the paradigm for AIDS pathogenesis by demonstrating the highly dynamic nature of HIV replication in vivo. Their groundbreaking studies on HIV dynamics formed the foundation for combination antiretroviral therapy, which Dr. Ho also helped to champion. Such a treatment approach has transformed HIV from a death sentence to a manageable disease, and is now being applied widely throughout the developing world.

Dr. David Ho said, "I am excited to join IsoPlexis as a Scientific Advisory Board member. By merging the top minds in engineering with leading researchers and clinicians, IsoPlexis is able to offer breakthrough clinical insights. As the company's applications expand, it has the potential to make significant progress on critical detection issues, enabling the advancement of various immune therapies."

ABOUT ISOPLEXIS:
IsoPlexis is a life sciences company committed to advancing groundbreaking research and therapeutic development in immunology, oncology and other emerging disease areas. The IsoPlexis cellular response analysis platform was developed by scientific leaders at Yale and Cal Tech. By isolating single immune cells and analyzing their functional omic response, the platform can assess safety and efficacy of therapeutics and monitor disease progression, enabling improved therapeutic development and patient outcomes. Through collaborations with leading pharmaceutical companies and academic labs, the IsoPlexis technology is improving the targeting of breakthrough treatments. The venture capital-funded Yale spinout is headquartered in Branford, Connecticut. For additional information on IsoPlexis, visit http://www.isoplexis.com or email [email protected].

SOURCE IsoPlexis Corporation

Related Links

http://www.isoplexis.com